Home Cart Sign in  
Chemical Structure| 950769-58-1 Chemical Structure| 950769-58-1

Structure of Quizartinib
CAS No.: 950769-58-1

Chemical Structure| 950769-58-1

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Quizartinib (AC220) is an orally active, highly selective, and potent second-generation type II FLT3 tyrosine kinase inhibitor with a Kd of 1.6 nM.Quizartinib inhibits wild-type FLT3 and FLT3-ITD autophosphorylation in MV4-11 cells with IC50 values of 4.2 and 1.1 nM, respectively, and can be linked to the VHL ligand via an optimized linker to form a PROTAC FLT3 degrader, inducing apoptosis.

Synonyms: AC220

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Quizartinib

CAS No. :950769-58-1
Formula : C29H32N6O4S
M.W : 560.67
SMILES Code : O=C(NC1=CC=C(C2=CN3C(SC4=CC(OCCN5CCOCC5)=CC=C34)=N2)C=C1)NC6=NOC(C(C)(C)C)=C6
Synonyms :
AC220
MDL No. :MFCD18074524
InChI Key :CVWXJKQAOSCOAB-UHFFFAOYSA-N
Pubchem ID :24889392

Safety of Quizartinib

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Quizartinib

RTK

Isoform Comparison

Biological Activity

Description
Quizartinib (AC220) is an orally bioavailable, highly selective, and potent second-generation type II FLT3 tyrosine kinase inhibitor, with a Kd of 1.6 nM. It effectively inhibits both wild-type FLT3 and FLT3-ITD autophosphorylation in MV4-11 cells, with IC50 values of 4.2 and 1.1 nM, respectively. Additionally, Quizartinib can be conjugated to the VHL ligand through an optimized linker to develop a PROTAC FLT3 degrader. Furthermore, Quizartinib induces apoptosis[1].
Target
  • FLT3

    FLT3 (WT), IC50:4.2 nM

    FLT3 (ITD), IC50:1.1 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
MV4;11 10 nM 24 h To evaluate the effect of FLT3 inhibition on BCL-XL and MCL-1 protein expression. Results showed that quizartinib significantly reduced BCL-XL and MCL-1 protein expression but did not alter BCL-2 expression. PMC8017817
Molm13 10 nM 24 h To evaluate the effect of FLT3 inhibition on BCL-XL and MCL-1 protein expression. Results showed that quizartinib significantly reduced BCL-XL and MCL-1 protein expression but did not alter BCL-2 expression. PMC8017817
FLT3(ITD); TET2mut AML cells 50 nM 3-5 days To test the effect of Quizartinib on FLT3(ITD); TET2mut AML cells in BMM conditions, results showed that Quizartinib inhibited the clonogenic activity of cells in BMM. PMC7578922
FLT3(ITD); Tet2−/− AML-like cells 100 nM 3-5 days To test the effect of Quizartinib on FLT3(ITD); Tet2−/− AML-like cells in BMM conditions, results showed that Quizartinib inhibited the clonogenic activity of cells in BMM. PMC7578922
FLT3ITD;NPM1mut AML cells 10 nM 72 h To assess the sensitivity of FLT3ITD;NPM1mut AML cells to Quizartinib, results showed that the sensitivity to Quizartinib was not affected by TET2mut and DNMT3Amut. PMC8487956
MV4-11 cells 0.16 nM 48 h To evaluate the growth inhibitory effect of Foretinib on MV4-11 cells carrying FLT3-ITD mutations, results showed that Foretinib effectively inhibited the growth of MV4-11 cells with an IC50 value of 0.16 nM PMC10940854
MOLM13 cells 0.89 nM 48 h To evaluate the growth inhibitory effect of Foretinib on MOLM13 cells carrying FLT3-ITD mutations, results showed that Foretinib effectively inhibited the growth of MOLM13 cells with an IC50 value of 0.89 nM PMC10940854
MV4;11 cells 18 nM To evaluate the inhibitory effect of PLX3397 on FLT3-ITD signaling PMC4522415
RS4;11 cells 1.8 μM To evaluate the inhibitory effect of PLX3397 on native FLT3 signaling PMC4522415
MV4-11 0.556 nM 48 h To determine the anti-proliferative activity of sitravatinib on MV4-11 cells, the results showed that sitravatinib significantly inhibited MV4-11 cells with an IC50 value of 0.556 nM PMC9872318
MOLM13 1.511 nM 48 h To determine the anti-proliferative activity of sitravatinib on MOLM13 cells, the results showed that sitravatinib significantly inhibited MOLM13 cells with an IC50 value of 1.511 nM PMC9872318
MOLM-13 3 nM 48 h To investigate the effect of quizartinib on apoptosis in FLT3-ITD AML cells, results showed that hBMSC-CM significantly reduced quizartinib-induced apoptosis. PMC9645811
MV4-11 3 nM 48 h To investigate the effect of quizartinib on apoptosis in FLT3-ITD AML cells, results showed that hBMSC-CM significantly reduced quizartinib-induced apoptosis. PMC9645811

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice FLT3-ITD+ acute myeloid leukemia model Oral 2.5 mg/kg or 5 mg/kg Once daily for 21 days To evaluate the impact of quizartinib combined with venetoclax on survival and tumor burden in FLT3-ITD+ leukemic mice. Results showed that the combination significantly prolonged survival and reduced tumor burden compared to monotherapy. PMC8017817
Mice FLT3(ITD); Tet2−/− AML-like leukemia model Not specified 1 mg/kg 7 consecutive days To test the anti-leukemia effect of Quizartinib in the FLT3(ITD); Tet2?/? AML-like leukemia model, results showed that Quizartinib significantly reduced the number of leukemia cells. PMC7578922
mice Flt3ITD;Tet2−/−, Flt3ITD;Dnmt3a−/− and Flt3ITD;Tet2−/−;Dnmt3a−/− leukemia models intravenous injection 1 mg/kg 14 consecutive days To evaluate the therapeutic effect of Quizartinib and Talazoparib on Flt3ITD;Tet2?/?, Flt3ITD;Dnmt3a?/? and Flt3ITD;Tet2?/?;Dnmt3a?/? leukemia models, results showed that Talazoparib alone or in combination with Quizartinib significantly inhibited Flt3ITD;Tet2?/? and Flt3ITD;Tet2?/?;Dnmt3a?/? leukemia, but was ineffective against Flt3ITD;Dnmt3a?/? leukemia. PMC8487956
Mice CMML-like disease model Oral 10 mg/kg Once daily for 6 weeks The JAK inhibitor ruxolitinib significantly reduced the development of CMML-like disease, while the FLT3 inhibitor quizartinib was less effective. PMC5495118
Mice FLT3-ITD AML mouse model Oral 10 mg/kg Daily administration for 2 weeks To evaluate the antileukemia activity of Quizartinib in the FLT3-ITD AML mouse model, results showed that Quizartinib significantly reduced leukemia cells in the bone marrow and spleen, and prolonged the survival of mice PMC10940854
Mice MV4;11 xenograft model Oral 10 mg/kg and 30 mg/kg Daily administration for 21 days To evaluate the inhibitory effect of PLX3397 on FLT3-ITD-driven MV4;11 xenograft tumors PMC4522415
Mice MOLM13 xenograft model Oral 10 mg/kg Once daily for 14 days To evaluate the anti-tumor efficacy of quizartinib in the MOLM13 xenograft model, the results showed that quizartinib significantly prolonged the survival of mice PMC9872318
Mice NRG-S mouse model Oral 2.5 mg/kg Once daily for 5 days or 84 days To investigate the effect of quizartinib alone or in combination with everolimus on leukemia burden in FLT3-ITD AML mouse models, results showed that the combination therapy significantly reduced leukemia burden in the bone marrow and prevented relapse. PMC9645811

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT01390337 Leukemia, Myeloid, Acute Phase 1 Completed - United States, Florida ... More >> Mayo Clinic Jacksonville Jacksonville, Florida, United States, 32224 United States, Illinois Northwestern University Chicago, Illinois, United States, 60611 United States, Maryland Johns Hopkins Medical Institute Baltimore, Maryland, United States, 21231 United States, New York Memorial-Sloan Kettering Cancer Center New York, New York, United States, 10065 United States, Texas M.D. Anderson Cancer Center Houston, Texas, United States, 77030 Less <<
NCT02428543 Acute Myeloid Lukemia Phase 1 Phase 2 Recruiting September 2020 France ... More >> Dr Abdelaziz CHAIB Recruiting Aix-en-Provence, France, 13600 Contact: Abdelaziz CHAIB       achaib@ch-aix.fr    Principal Investigator: Abdelaziz CHAIB          Chu Amiens Recruiting Amiens, France, 80054 Contact: MAROLLEAU Jean Pierre          Principal Investigator: MAROLLEAU Jean Pierre          CHU d'Angers Recruiting Angers, France, 49033 Contact: Martine GARDEMBAS       Magardembas@chu-angers.fr    Principal Investigator: Martine GARDEMBAS          Hôpital VICTOR DUPOUY Recruiting Argenteuil, France, 95107 Contact: AL JIJAKLI Ahmad       ahmad.aljijakli@ch-argenteuil.fr    Principal Investigator: AL JIJAKLI Ahmad          Dr Edouard RANDIAMALALA Recruiting Bayonne, France, 64100 Contact: Edouard RANDIAMALALA       erandiamalala@ch-cotebasque.fr    Principal Investigator: Edouard RANDIAMALALA          CHU de Besançon Recruiting Besançon, France, 25030 Contact: Fabrice LAROSA       flarosa@chu-besançon.fr    Principal Investigator: Fabrice LAROSA          Dr Thorsten BRAUN Recruiting Bobigny, France, 93000 Contact: Thorsten BRAUN       thorsten.braun@aphp.fr    Principal Investigator: Thorsten BRAUN          CHU Boulogne Sur Mer Recruiting Boulogne Sur Mer cedex, France, 62321 Contact: CHOUFI Bachra       b.choufi@ch-boulogne.fr    Principal Investigator: CHOUFI Bachra          Chr Clemenceau Recruiting Caen Cedex, France, 14033 Contact: REMAN Oumédaly       reman-o@chu-caen.fr    Principal Investigator: REMAN Oumédaly          Hôpital d'Instruction des Armées PERCY Recruiting Clamart, France, 92141 Contact: Jean Valère MALFUSSON       jvmalf@free.fr    Principal Investigator: Jean Valère MALFUSSON          Dr Stéphanie HAÏAT Recruiting Corbeil-essonnes, France, 91100 Contact: Stéphanie HAÏAT          Principal Investigator: Stéphanie HAÏAT          Hôpital Henri Mondor Recruiting Créteil, France, 94010 Contact: PAUTAS Cécile       cecile.pautas@hmn.aphp.fr    Principal Investigator: PAUTAS Cécile          CHU de Dijon Not yet recruiting Dijon, France, 21079 Contact: CAILLOT Denis       denis.caillot@chu-dijon.fr    Principal Investigator: CAILLOT Denis          Centre hospitalier de Versailles Recruiting Le Chesnay cedex, France, 78157 Contact: Rousselot Philippe    003339638622    phrousselot@ch-versailles.fr    Principal Investigator: Rousselot Philippe          Hôpital Claude Huriez Recruiting Lille cedex, France, 59037 Contact: QUESNEL Bruno       bquesnel@chru-lille.fr    Principal Investigator: QUESNEL Bruno          CHRU Dupuytren Not yet recruiting Limoges cedex, France, 87042 Contact: TURLURE Pascal       pascal.turlure@chu-limoges.fr    Principal Investigator: TURLURE Pascal          Hôpital Edouard Herriot Recruiting Lyon cedex 03, France, 69437 Contact: THOMAS Xavier       xavier.thomas@chu-lyon.fr    Principal Investigator: THOMAS Xavier          Dr Regis COSTELLO Recruiting Marseille, France, 13000 Contact: Regis COSTELLO       regis.costello@ap-hm.fr    Principal Investigator: Regis COSTELLO          Centre Hospitalier de Meaux Recruiting Meaux, France, 77104 Contact: FRAYFER Jamilé       j-frayfer@ch-meaux.fr    Principal Investigator: FRAYFER Jamilé          Dr Mario OJEDA-URIBE Recruiting Mulhouse, France, 68000 Contact: Mario OJEDA-URIBE       ojedam@ch-mulhouse.fr    Principal Investigator: Mario OJEDA-URIBE          Dr Jacques DELAUNAY Recruiting Nantes, France, 44000 Contact: Jacques DELAUNAY       jacques.delaunay@chu-nantes.fr    Principal Investigator: Jacques DELAUNAY          CHU Nice, Hôpital Archet 1 Recruiting Nice cedex 3, France, 06202 Contact: MANNONE Lionel       mannone.l@chu-nice.fr    Principal Investigator: MANNONE Lionel          CHU de Nîmes Recruiting Nîmes, France, 30029 Contact: Eric JOURDAN       eric.jourdan@chu-nimes.fr    Principal Investigator: Eric Jourdan          Hôpital Saint Antoine Recruiting Paris cedex 12, France, 75751 Contact: ISNARD Françoise       francoise.isnard@sat.aphp.fr    Principal Investigator: ISNARD Françoise          Hôpital Necker Enfants Malades Recruiting Paris cedex 15, France, 75743 Contact: SUAREZ Felipe       felipe.suarez@nck.aphp.fr    Principal Investigator: SUAREZ Felipe          Hôpital Saint Louis Recruiting Paris, France, 75010 Contact: RAFFOUX Emmanuel       emmanuel.raffoux@sls.ap-hop-paris.fr    Principal Investigator: RAFFOUX Emmanuel          Hôpital La Pitié Salpêtrière Recruiting Paris, France, 75013 Contact: UZUNOV Madalina       madalina.uzunov@psl.aphp.fr    Principal Investigator: UZUNOV Madalina          Dr Laurence SANHES Suspended Perpignan, France, 66000 Dr Arnaud PIGNEUX Recruiting Pessac, France, 33604 Contact: Arnaud PIGNEUX       arnaud.pigneux@chu-bordeaux.fr    Principal Investigator: Arnaud PIGNEUX          Centre Hospitalier René Dubos Recruiting Pontoise Cedex, France, 95303 Contact: VAIDA Iona Dana       ioana.vaida@ch-pontoise.fr    Principal Investigator: VAIDA Iona Dana          Marc BERNARD Recruiting Rennes, France, 35000 Contact: Marc BERNARD       marc.bernard@chu-rennes.fr    Principal Investigator: Marc BERNARD          Dr Emilie LEMASLE Recruiting Rouen, France, 76000 Contact: Emilie LEMASLE       emilie.lemasle@chb.unicancer.fr    Principal Investigator: Emilie LEMASLE          Centre Hospitalier René Huguenin Suspended Saint Cloud, France, 92210 Institut de Cancérologie de la Loire Recruiting Saint-Priest-en-Jarez, France, 42270 Contact: Emmanuelle TAVERNIER-TARDY       emmanuelle.tavernier@icloire.fr    Principal Investigator: Emmanuelle TAVERNIER-TARDY          Dr Réda GARIDI Recruiting Saint-Quentin, France, 02100 Contact: Réda GARIDI          Principal Investigator: Réda GARIDI          Dr Christian RECHER Recruiting Toulouse, France, 31000 Contact: Christian RECHER          Principal Investigator: Christian RECHER          Centre Hospitalier de Valenciennes Recruiting Valenciennes, France, 59322 Contact: FERNANDES José       fernandes-j@ch-valenciennes.fr    Principal Investigator: FERNANDES José Less <<
NCT00462761 Acute Myeloid Leukemia|Leukemi... More >>a|Myelodysplastic Syndrome|AML|MDS Less << PHASE1 COMPLETED 2025-12-09 University of Alabama at Birmi... More >>ngham, Birmingham, Alabama, 35294, United States|University of Nebraska Medical Center, Omaha, Nebraska, 68198, United States|MD Anderson Cancer Center, Houston, Texas, 77030, United States|Chemotherapy and Immunotherapy Clinic, T'Bilisi, Georgia|Hematology and Chemotherapy Clinic, T'bilisi, Georgia Less <<
NCT02829840 Leukemia FLT3... More >>-Mutated Acute Myeloid Leukemia FLT3-Mutated High-Risk Myelodysplastic Syndrome Less << Phase 1 Phase 2 Withdrawn - -
NCT01468467 Leukemia, Myeloid, Acute PHASE1 COMPLETED 2025-03-15 City of Hope, Duarte, Californ... More >>ia, 91010, United States|Northwestern University, Chicago, Illinois, 60611, United States|University of Minnesota, Minneapolis, Minnesota, 55455, United States|M.D. Anderson Cancer Center, Houston, Texas, 77030, United States|Seattle Cancer Care Alliance, Seattle, Washington, 98109, United States Less <<
NCT01576185 - Completed - United States, California ... More >> Children's Oncology Group Monrovia, California, United States, 91006-3776 Less <<
NCT02675478 Relapsed AML|Refractory AML PHASE1 COMPLETED 2018-11-13 Tokyo, Japan
NCT02668653 Acute Myeloid Leukemia ... More >> Leukemia Less << Phase 3 Recruiting November 2020 -
NCT02039726 AML Phase 3 Active, not recruiting July 2019 -
NCT01892371 FLT3 Gene Mutation ... More >> Recurrent Acute Myeloid Leukemia Recurrent Chronic Myelomonocytic Leukemia Recurrent Myelodysplastic Syndrome Refractory Acute Myeloid Leukemia Refractory Chronic Myelomonocytic Leukemia Refractory Myelodysplastic Syndrome Less << Phase 1 Phase 2 Recruiting November 30, 2019 United States, Texas ... More >> M D Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Contact: Jorge E. Cortes    713-794-5783       Principal Investigator: Jorge E. Cortes Less <<
NCT03552029 Acute Myeloid Leukemia Phase 1 Recruiting October 15, 2021 United States, Texas ... More >> MD Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Contact: Principal Investigator    713-794-4392    NDaver@mdanderson.org Less <<
NCT02834390 Acute Myeloid Leukemia Phase 1 Completed - Japan ... More >> Tokyo, Japan Less <<
NCT02984995 Leukemia, Myeloid, Acute PHASE2 COMPLETED 2018-09-14 Aichi, Japan|Akita, Japan|Chib... More >>a, Japan|Fukui, Japan|Fukuoka, Japan|Fukushima, Japan|Gifu, Japan|Gunma, Japan|Hiroshima, Japan|Hokkaido, Japan|Ibaraki, Japan|Kagoshima, Japan|Kanagawa, Japan|Kyoto, Japan|Miyagi, Japan|Nagasaki, Japan|Nara, Japan|Okayama, Japan|Osaka, Japan|Saga, Japan|Saitama, Japan|Shizuoka, Japan|Tochigi, Japan|Tokyo, Japan|Toyama, Japan|Yamagata, Japan|Yamanashi, Japan Less <<
NCT03735875 Acute Myeloid Leukemia With FL... More >>T3/ITD Mutation FLT3 Gene Mutation FLT3 Internal Tandem Duplication Recurrent Acute Myeloid Leukemia Refractory Acute Leukemia Less << Phase 1 Phase 2 Not yet recruiting December 31, 2019 United States, Texas ... More >> M D Anderson Cancer Center Not yet recruiting Houston, Texas, United States, 77030 Contact: Naval G. Daver    713-794-4392       Principal Investigator: Naval G. Daver Less <<
NCT01565668 Leukemia, Myeloid, Acute PHASE2 COMPLETED 2025-03-15 UCLA School of Medicine, Los A... More >>ngeles, California, 90095, United States|Northwestern University, Chicago, Illinois, 60611, United States|University of Chicago, Chicago, Illinois, 60637, United States|University of Maryland Greenebaum Cancer Center, Baltimore, Maryland, 21201, United States|John Hopkins University, Baltimore, Maryland, 21231, United States|Tufts University School of Medicine-Tufts Medical Center, Boston, Massachusetts, 02111, United States|University of Minnesota, Minneapolis, Minnesota, 55455, United States|Mayo Clinic, Rochester, Minnesota, 55905, United States|Hackensack University Medical Center, Hackensack, New Jersey, 07601, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, 10021, United States|Weill Cornell Medical College, New York, New York, 10065, United States|Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, 17033, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, 19104, United States|Medical University of South Carolina, Hollings Cancer Center, Charleston, South Carolina, 29403, United States|Vanderbilt University, Vanderbilt Ingram Cancer Center, Nashville, Tennessee, 37232, United States|UT Southwestern Medical Center, Simmons Cancer Center, Dallas, Texas, 75390, United States|MD Anderson, Houston, Texas, 77030, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, 98109, United States|CHU d'Angers, Angers, 49033, France|CHU de Grenoble, Grenoble, 38043, France|H?pital Saint Antoine, Paris, 75571, France|H?pital Haut Lévêque, Pessac, 33600, France|Universitaria Policlinico S. Orsola Malpighi, Institute of Hemtology "L. & A. Seragnoli", Bologna, 40138, Italy|Nottingham University Hospitals, Nottingham, England, United Kingdom Less <<
NCT03723681 Acute Myeloid Leukemia (AML) PHASE1 COMPLETED 2022-03-03 Institute of Hematology and Bl... More >>ood Diseases Hospital Chinese Academy of Medical Sciences, Tianjin, 300020, China Less <<
NCT03135054 AML FLT3-ITD ... More >>Mutation Less << Phase 2 Recruiting October 1, 2021 Hong Kong ... More >> The University of Hong Kong Recruiting Hong Kong, Hong Kong Contact: Chunxiao Zhang, SC    852-22554361    chunxiao@hku.hk Less <<
NCT03661307 Acute Myeloid Leukemia With FL... More >>T3/ITD Mutation Blasts More Than 10 Percent of Bone Marrow Nucleated Cells Blasts More Than 10 Percent of Peripheral Blood White Cells Myelodysplastic Syndrome Recurrent Acute Myeloid Leukemia Recurrent Myelodysplastic Syndrome Less << Phase 1 Phase 2 Recruiting January 1, 2020 United States, Texas ... More >> M D Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Contact: Musa Yilmaz    713-745-9945       Principal Investigator: Musa Yilmaz Less <<
NCT03746912 - - - -
NCT06740799 Hepatic Impairment PHASE1 RECRUITING 2025-06-30 Clinical Pharmacology of Miami... More >>, LLC, Miami, Florida, 33014, United States|Advanced Pharma, Miami, Florida, 33147, United States|GCP Research, Saint Petersburg, Florida, 33705, United States Less <<
NCT04473664 Hepatic Impairment|Moderate Im... More >>paired Hepatic Function Less << PHASE1 COMPLETED 2021-07-22 Clinical Pharmacology of Miami... More >>, LLC, Miami, Florida, 33014-3616, United States|Advanced Pharma, Miami, Florida, 33147, United States|Orlando Clinical Research Center, Orlando, Florida, 32809, United States Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.78mL

0.36mL

0.18mL

8.92mL

1.78mL

0.89mL

17.84mL

3.57mL

1.78mL

References

 

Historical Records

Categories